International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 09 September 2023

Page No: 2108-2111

DOI: https://doi.org/10.47191/ijmscrs/v3-i9-54, Impact Factor: 6.59

Necrobiosis Lipoidica: An Exquisite Analysis of its Pathogenesis, Clinical Presentation, and Current Therapeutic Approaches

Laura Yoana Cervantes Ramírez[1], Aldo Sinue Cruz González[2], Cesar Made Padilla[2], Alan Eduardo Garzón Navarrete[3], Adriana Yazmín Ramos Ramírez[2], María Fernanda Aguilar Orozco[4]

[1]Hospital General de Zona 2 del Instituto Mexicano del Seguro Social, Aguascalientes, México.
[2]Universidad de Guadalajara, Centro Universitario del Sur. Ciudad Guzman Jalisco, México.
[3]Universidad Guadalajara LAMAR Campus Vallarta. Guadalajara Jalisco. México.
[4]Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud. Guadalajara Jalisco, México.

ABSTRACT

Necrobiosis lipoidica (NL) is a rare dermatologic disease of uncertain origin characterized by the appearance of chronic, deep cutaneous lesions, predominantly on the legs of patients with type 1 diabetes mellitus. This article comprehensively addresses NL, exploring its intricate pathogenesis, clinical manifestations, and current therapeutic options.

NL has become a clinical challenge due to its chronic and often refractory nature. Its connection with type 1 diabetes mellitus and the possible contribution of autoimmune factors in its development are highlighted. In addition, theories involving inflammation, microangiopathy, and collagen disruption as key components of its pathogenesis are discussed.

The clinical presentation of NL is varied, ranging from well-demarcated erythematous plaques to painful and disfiguring ulcers. Differential diagnoses are meticulously addressed, and imaging techniques and skin biopsies are described as essential tools in diagnostic confirmation.

In terms of therapeutic options, pharmacological approaches such as topical corticosteroids, immunomodulators, and emerging biologic therapies are discussed. The efficacy and safety of these options are critically evaluated, highlighting the need for a personalized approach for each patient.

In summary, this article provides a comprehensive overview of necrobiosis lipoidica, from its underlying mechanisms to currently available treatment strategies. A thorough understanding of this clinical entity is essential to improve the quality of life of affected patients and to advance the search for more effective therapies in the future.

ARTICLE DETAILS

Published On:
29 September 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Necrobiosis lipoidica (NL) is a rare, chronic dermatologic entity that has intrigued clinicians and scientists for decades due to its multifaceted and clinically challenging nature. This condition, although rare in the general population, has attracted significant interest in the medical community due to its association with type 1 diabetes mellitus, as well as its complex pathogenesis and lack of consensus on optimal therapeutic options.1

NL manifests clinically as skin lesions, ranging from erythematous, atrophic, well-demarcated plaques to painful ulcers, predominantly affecting the lower extremities. Its variable presentation, which may include asymptomatic or debilitating symptoms, poses a diagnostic challenge for dermatologists and other health care professionals. In addition, their recurrence and refractoriness to conventional therapies have generated continued interest in the search for more effective and personalized therapeutic approaches.1,2

A comprehensive understanding of NL requires a thorough examination of its pathogenesis, which involves complex interactions between genetic factors, autoimmunity, microangiopathy, inflammation, and alterations in the extracellular matrix. Despite decades of research, a complete understanding of the underlying mechanisms leading to the development and progression of NL has yet to be achieved, underscoring the need for continued research in this area.3

This article aims to provide a comprehensive review of NL, addressing its epidemiological aspects, etiopathogenesis, clinical manifestations, differential diagnosis, and current therapeutic options. Through a rigorous and evidence-based approach, it seeks to contribute to the current knowledge of NL, as well as to the improvement of clinical care of affected patients and the identification of possible areas for future research in this fascinating dermatologic entity.4

EPIDEMIOLOGY

Necrobiosis lipoidica (NL) is a rare chronic dermatologic disease of significant clinical relevance due to its well-documented association with type 1 diabetes mellitus (DM1) and its impact on patients' quality of life. Despite its low prevalence in the general population, its relationship with DM1 emphasizes the need for a thorough understanding of this clinical entity in the medical community.4

From an epidemiological point of view, NL exhibits a variable prevalence in patients with DM1, with estimates ranging from 0.3% to 2.8%, according to various studies. While this figure may seem modest, it should be considered that DM1, as an underlying condition, already affects millions of individuals worldwide. The coexistence of NL and DM1 not only adds an additional burden for these patients, but also raises questions about the complex pathophysiological interactions between the two diseases.4

The clinical relevance of NL lies in its potential to generate substantial morbidity. Characteristic skin lesions can cause painful and stigmatizing symptoms, which can affect patients' quality of life. In addition, NL may be an early cutaneous manifestation of DM1, underscoring its importance as a clinical marker for the early detection of diabetes in at-risk individuals.4

From a therapeutic perspective, NL presents a clinical challenge, as its response to treatment is variable and often suboptimal. The lack of standardized and effective therapeutic approaches emphasizes the need for further research to develop more specific and personalized therapeutic strategies.4

In summary, the epidemiology of NL, particularly its close linkage with DM1, highlights its clinical relevance and potential impact on patients' quality of life. Furthermore, the lack of definitive therapeutic options highlights the continued importance of clinical and basic research in the field of NL to improve the care and quality of life of affected individuals.5

CLINICAL MANIFESTATIONS

Necrobiosis lipoidica (NL) manifests as a chronic and complex dermatologic entity, characterized by a number of varied clinical manifestations that have a marked potential to impact the quality of life of affected patients. This comprehensive clinical overview of NL will meticulously address the intrinsic clinical features of this disease, including its typical and atypical presentations, as well as related symptoms.6

The cutaneous lesions of NL exhibit a wide spectrum of clinical appearance. They usually present as erythematous, atrophic, well-demarcated plaques with a yellowish center due to lipid degeneration in the subcutaneous adipose tissue. These plaques can vary in size and shape, from small macules to large extensive areas. However, it is important to note that the manifestations of NL can be highly variable between individuals, which can sometimes make it difficult to diagnose.7

A distinguishing feature of NL is its tendency to ulceration, which manifests in approximately 30% of patients. These ulcers are often painful and slow healing, which significantly exacerbates the morbidity associated with the disease. NL ulcers can be disfiguring and are often subject to secondary infections, which can further complicate their clinical management.8

In addition to skin lesions, many patients with NL may experience pruritic and painful symptoms in the affected areas, contributing to considerable physical and emotional discomfort. These symptoms can vary in intensity and can influence quality of life substantially.8

The preferential distribution of lesions in NL is on the lower extremities, especially the shins, although it can also affect other areas of the body less frequently. It is important to mention that the symmetry in the distribution of lesions is not invariable and may vary from patient to patient.8

The clinical complexity of NL is compounded by its potential ability to mimic other dermatologic conditions, which poses a challenge in differential diagnosis. In summary, NL manifests with a wide range of clinical features, from typical plaques to painful ulcers, pruritus and a preferential distribution on the lower extremities, underscoring its heterogeneous nature and potentially significant clinical impact.9

DIAGNOSIS

The diagnosis of necrobiosis lipoidica (NL) represents a clinical challenge that requires a thorough and accurate evaluation, considering a variety of clinical, histopathologic, and differential diagnostic criteria. Meticulousness in the diagnostic evaluation is essential to confirm the presence of this unique dermatologic entity and, at the same time, exclude other skin conditions with similar presentations.10

Clinical evaluation constitutes the first pillar of the diagnosis of NL. Characteristic clinical findings include the presence of well-demarcated erythematous plaques with a yellowish center on the lower extremities, especially on the shins. It is crucial to examine the morphology and distribution of the lesions, as well as to take into account subjective symptoms such as pruritus and pain. In addition, detailed information on the patient's medical history should be obtained, including the

presence of type 1 diabetes mellitus, since NL is closely associated with this metabolic disease.10

Diagnostic confirmation of NL requires the performance of a skin biopsy. This procedure provides microscopic insight into the distinctive histopathologic features of the disease, which include lipid degeneration in the subcutaneous adipose tissue, the presence of vascular changes such as microangiopathy, and perivascular inflammation. Identification of these features on biopsy is critical in establishing the diagnosis of NL, as they may be pathognomonic of the disease.11

Differential diagnosis is a critical aspect in the evaluation of NL because of its ability to mimic other skin conditions, such as granuloma annulare, nummular dermatitis, cutaneous sarcoidosis, discoid lupus erythematosus, and others. Distinguishing between these entities often requires a thorough clinical examination, biopsy data and, in some cases, additional laboratory testing to rule out systemic diseases with similar skin manifestations.11

Diagnosis of necrobiosis lipoidica involves a comprehensive evaluation combining clinical assessment, skin biopsy and careful differential diagnosis to definitively confirm the presence of this dermatologic disease. The combination of these approaches is essential to ensure accurate identification and subsequent appropriate management of affected patients.12

DIAGNOSIS

The treatment of necrobiosis lipoidica (NL) is a clinical challenge that involves meticulous consideration of various therapeutic modalities, depending on the severity of the disease, the individual patient's response and the presence of comorbidities, particularly type 1 diabetes mellitus. Although a universally accepted therapeutic approach is lacking due to the heterogeneous nature of NL and its low prevalence, several therapeutic strategies have been developed and explored with the aim of improving patients' quality of life and reducing associated complications.13

Topical therapy: Topical corticosteroids, such as clobetasol propionate, have traditionally been used to reduce inflammation and relieve the pruritic symptoms of NL.

The application of topical immunomodulatory agents, such as tacrolimus or pimecrolimus, may be beneficial in selected cases.13

Systemic Therapy:

Systemic corticosteroids, such as prednisone, may be considered in severe or refractory cases, although their long-term use can lead to significant side effects and requires careful monitoring.13

Systemic immunomodulators, such as methotrexate or azathioprine, have been used in resistant cases, although their efficacy can be variable.13

Biological Therapy:

Tumor necrosis factor-alpha (TNF-alpha) inhibitors, such as infliximab or adalimumab, have shown promise in small studies and isolated cases of severe NL.13

Therapy with rituximab, an anti-CD20 monoclonal antibody, has also been evaluated in patients with NL resistant to other therapies.

Ultraviolet Light Therapy:

Ultraviolet (UV) light therapy may be beneficial in some cases of NL, especially when lesions are recalcitrant and painful.

Narrowband ultraviolet B (UVB) radiation has been shown to be useful in the remission of skin lesions.13

Local Treatments: Intralesional corticosteroid injections may be an option to treat single or ulcerated lesions of NL.14

Laser therapy, such as fractional CO2 laser, has been proposed as an option to improve the appearance of scars and reduce inflammation.14

Importantly, the choice of treatment should be individualized and carefully consider the risks and benefits, as well as the patient's response. Given the chronic nature of NL and the lack of definitive therapeutic options, the management of this disease may require a multidisciplinary approach, involving dermatologists, endocrinologists and other specialists according to the patient's needs.14

The development of more targeted and personalized therapies for NL remains an active research goal, and continued understanding of the pathogenesis of the disease promises to open new therapeutic avenues in the future.14

CONCLUSION

Necrobiosis lipoidica (NL) emerges as a uniquely complex dermatologic entity, characterized by its heterogeneous clinical presentation, its association with type 1 diabetes mellitus, and its ongoing therapeutic challenge. This article has comprehensively addressed this rare cutaneous pathology from various perspectives, providing a comprehensive view of its epidemiological, pathogenetic, clinical and therapeutic aspects.

The epidemiology of NL has revealed a close relationship with type 1 diabetes mellitus, highlighting the importance of dermatologic surveillance and follow-up in diabetic patients. Furthermore, the variable prevalence of NL and its ability to affect the quality of life of affected individuals highlight the clinical relevance of this entity, even in a relatively small population of patients.

From a pathogenetic perspective, NL raises continuing questions about the underlying mechanisms leading to its development and progression. The presence of microangiopathic, inflammatory changes and collagen disruption in lesions suggests a complex interplay of factors, but gaps remain in the complete understanding of its etiopathogenesis. Research in this field remains essential to identify potential therapeutic targets and more precise strategies.

The clinic of NL, as described in this article, presents a wide range of manifestations that vary in intensity and morphology, which often complicates its diagnosis and its differentiation from other dermatologic diseases. Accurate diagnosis, based on clinical criteria and supported by histopathology, is crucial to ensure appropriate management and multidisciplinary care, especially in patients with comorbidities.

In terms of treatment, NL challenges clinicians to apply individualized therapeutic approaches tailored to the severity of the disease and the patient's response. While various therapeutic modalities have been explored, there is no universally accepted approach due to variability in efficacy and patient tolerance. Continued research and the search for more targeted therapies represent hope for improved long-term care.

In summary, NL is a complex dermatologic entity that requires a thorough understanding and a multidisciplinary approach. A combination of sound research, meticulous clinical evaluation and individualized therapeutic management are essential elements in effectively addressing this rare skin disease. As progress is made in understanding its pathogenesis and identifying more effective therapeutic approaches, care for patients with NL is expected to improve significantly in the future.

REFERENCES

I. Muller SA, Winkelmann RK. Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol. 1966;93(3):272-81.

II. Erfurt-Berge C, Seitz AT, Rehse C, Wollina U, Schwede K, Renner R. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. Eur J Dermatol. 2012;22(6):770-5.

III. Engel MF, Smith JG Jr. The pathogenesis of necrobiosis lipoidica. Necrobiosis lipoidica, a form fruste of diabetes mellitus. Arch Dermatol. 1960;82:791-7.

IV. Ngo B, Wigington G, Hayes K, Huerter C, Hillman B, Adler M, et al. Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol. 2008;47(4):354-8.

V. O'Toole EA, Kennedy U, Nolan JJ, Young MM, Rogers S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol. 1999;140(2):283-6.

VI. 6.Marcoval J, Gómez-Armayones S, Valentí-Medina F, BonfillOrtí M, Martínez-Molina L. Necrobiosis lipoidica: a descriptive study of 35 cases. Actas Dermosifiliogr. 2015;106(5): 402-7.

VII. Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking, and proteinuria. A case controlled study. Diabet Med. 1993;10(8):725-8.

VIII. Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Der matol. 1991;25(5 Pt 1):735-48.

IX. Burillo-Martínez S, Maroñas-Jiménez L, Morales-Raya C, Gutiérrez García-Rodrigo C, Postigo-Llorente C, Rodríguez-Peralto JL. Necrobiosis lipoidica of the glans penis: a case report and literature review. J Dtsch Dermatol Ges. 2016; 14(10):1040-1.

X. Patel GK, Harding KG, Mills CM. Severe disabling Köebnerizing ulcerated necrobiosis lipoidica successfully managed with topical PUVA. Br J Dermatol. 2000;143(3):668-9.

XI. Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013;69(5):783-91.

XII. Santos-Juanes J, Galache C, Curto JR, Carrasco MP, Ribas A, Sánchez del Río J. Squamous cell carcinoma arising in longstanding necrobiosis lipoidica. J Eur Acad Dermatol Venereol. 2004;18(2):199-200.

XIII. García-Gavín J, Comba Pérez-Pérez L, Requena L, Wortsman X.Sarcoidal necrobiosis lipoidica in a nondiabetic patient: usefulness of skin ultrasound. Actas Dermosifiliogr. 2016;107(6): 525-7.

XIV. Conde-Montero E, Avilés-Izquierdo JA, Mendoza-Cembranos MD, Parra-Blanco V. Dermoscopy of necrobiosis lipoidica. Actas Dermosifiliogr. 2013;104(6):534-7.

XV. Herrera Ceballos E, Moreno Carazo A, Requena Caballero L, Rodríguez Peralto JL. Dermatopathology: clinicopathologic correlation. 1st ed. Madrid: Área Científica Menarini; 2007.

XVI. Lallas A, Zaballos P, Zalaudek I, Apalla Z, Gourhant JY, Longo C, et al. Dermoscopic patterns of granuloma annulare and necrobiosis lipoidica. Clin Exp Dermatol. 2013;38(4):425-7.

XVII. Chiba T, Takahara M, Nakahara T, Fukagawa S, Takei K, Shono A, et al. Cutaneous sarcoidosis clinically mimicking necrobiosis lipoidica in a patient with systemic sarcoidosis. Ann Dermatol. 2012;24(1):74-6.